Appeals Court Rejects Challenge To Alpharma's 180-Day Exclusivity For Pfizer's Neurontin
By Marius Meland ( December 22, 2004, 12:00 AM EST) -- The U.S. Court of Appeals for the District of Columbia has rejected a challenge to drug maker Alpharma Inc.'s exclusive right to market a generic version of the Pfizer Inc. epilepsy drug Neurontin....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.